Ampath National Laboratory Services.
S Afr Med J. 2010 Jun 1;100(6 Pt 2):388-94. doi: 10.7196/samj.4109.
Tigecycline, the first of a new class of antibiotics, the glycylcyclines, was licensed in South Africa for the parenteral treatment of adult patients with complicated intra-abdominal infections (cIAIs) and complicated skin and soft-tissue infections (cSSTIs).
A multidisciplinary meeting representative of the Association of Surgeons of South Africa, the Critical Care Society of Southern Africa, the Federation of Infectious Diseases Societies of Southern Africa, the South African Thoracic Society and the Trauma Society of South Africa was held to draw up a national guideline for the appropriate use of tigecycline. Background information reviewed included randomised controlled trials, other relevant publications and local antibiotic susceptibility patterns. The initial document was drafted at the meeting. Subsequent drafts were circulated to members of the working group for modification.
The guideline addresses several important aspects of the new agent, summarising key clinical data and highlighting important considerations with the use of the drug. The recommendations in this guideline are based on currently available scientific evidence together with the consensus opinion of the authors.
This statement was written out of concern regarding the widespread misuse of antibiotics. Its primary intention is to facilitate heterogeneous use of antibiotics as a component of antibiotic stewardship and to highlight the appropriate use of tigecycline in particular.
替加环素是新型抗生素甘氨酰环素类的首个药物，于南非获批用于治疗成人复杂性腹腔内感染（cIAI）和复杂性皮肤软组织感染（cSSTI）的静脉治疗。
南非外科医生协会、南非重症监护学会、南部非洲传染病学会联合会、南非胸科协会和南非创伤学会的多学科会议代表举行了一次会议，制定了替加环素的国家使用指南。回顾的背景信息包括随机对照试验、其他相关出版物和当地抗生素药敏模式。会议起草了初始文件，随后将草稿分发给工作组的成员进行修改。
该指南涉及新药物的几个重要方面，总结了关键的临床数据，并强调了使用该药物的重要注意事项。本指南中的建议是基于目前可用的科学证据以及作者的共识意见。
本声明是出于对抗生素广泛滥用的担忧而编写的。其主要目的是促进抗生素的异质使用，作为抗生素管理的一部分，并特别强调替加环素的合理使用。
